This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $682,000 to The Roskamp Institute, Inc. to investigate the influence of microglial cell depletion and repopulation on amyloid-related imaging abnormalities (ARIA) and vascular lesions in individuals with Alzheimer's disease who carry the APOE4 genotype. The study aims to characterize the impact of microglial activation on cerebrovascular integrity and function following treatment with the...
The National Institute on Aging awarded a $2,250,745 Project Grant (CFDA 93.866 - Aging Research) to Mayo Clinic Jacksonville, doing business as Scott Lynch MD, to conduct research on the role of apolipoprotein E (APOE) in meningeal lymphatic function and its impact on Alzheimer's disease pathophysiology. The research aims to uncover the effects of APOE4 expression on meningeal lymphatic drainage and immune cell interactions, and how this may contribute to neuroinflammation and amyloid-β...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $3,477,475 to the Icahn School of Medicine at Mount Sinai to investigate the combined role of the APOE4 gene variant and ketogenic diets in the development of Alzheimer's disease (AD). The award will fund a 5-year research study aimed at elucidating the molecular mechanisms by which APOE4 interacts with high-fat/ketogenic diets to exacerbate AD pathogenesis. The research will employ in vitro...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This $1,559,999 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports a comprehensive study to elucidate the regulation of the APOE gene and the role of the AANCR noncoding RNA in Alzheimer's disease. The research aims to gain a deeper understanding of how APOE expression and genotypes, particularly the risk-associated APOE4 allele, affect cellular function in stress-activated astrocytes and microglia, and the subsequent impact on neuronal health....
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research (CFDA 93.866) federal grant program, provides $660,875 to the University of Washington to investigate the protective effects of African-derived APOE alleles on Alzheimer's disease (AD) risk. The project aims to identify genetic variants on African-derived and European-derived APOE haplotypes that may contribute to the reduced AD risk associated with African APOE alleles, and to characterize the...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $804,450.00 to the J. David Gladstone Institutes in San Francisco, CA to investigate the mechanisms by which the Alzheimer's disease risk factor APOE4 and sex differences contribute to network hyperactivity and selective neuronal dysfunction in Alzheimer's disease. The research aims to validate the protective effects of the NELL2 protein in hippocampal excitatory neurons and examine...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $341,000 in funding to The Roskamp Institute, Inc. in Sarasota, FL to conduct research aimed at understanding and correcting brain bioenergetics defects associated with the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research will examine the influence of different APOE genotypes on the GLP-1R-AMPK-ACC pathway in cerebrovascular cells and astrocytes, and evaluate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $124,786 to The Regents of the University of California, San Francisco to determine the genetic drivers of ancestry-specific differential penetrance of APOE4 in sporadic Alzheimer's disease. The key activities include: Conducting massively parallel reporter assays in iPSC-derived brain cell types to functionally prioritize a comprehensive set of 10,661 analytically-nominated variants that...
INVESTIGATING NEUTROPHILIC INFLAMMATION AS AN APOE GENOTYPE-SPECIFIC MEDIATOR OF NEUROINFLAMMATION AND COGNITIVE DECLINE IN AGING - PROJECT SUMMARY THE PRESENCE OF THE 4 ALLELE OF APOE (APOE4) IS THE GREATEST GENETIC RISK FACTOR FOR LATE ONSET ALZHEIMER'S DISEASE (AD), INCREASING THE RISK APPROXIMATELY 12-FOLD WHEN HOMOZYGOUS FOR APOE4 COMPARED TO THE MOST COMMON APOE3/APOE3 GENOTYPE. HOWEVER, THE MECHANISMS BY WHICH DIFFERENT APOE ALLELES MEDIATE ALZHEIMER'S RISK ARE UNCLEAR. THE OVERALL GOALS FOR THIS STUDY ARE TO 1) INVESTIGATE NEUTROPHIL ACTIVATION AND LIFESPAN AS THERAPEUTIC TARGETS TO REDUCE AD RISK OR PROGRESSION IN THE CONTEXT OF DIFFERENT APOE GENOTYPES AND 2) IDENTIFY MICROBIAL INTERACTIONS THAT REPRESENT PROMISING TARGETS TO REDUCE NEUTROPHILIC INFLAMMATION IN THE CONTEXT OF DIFFERENT APOE GENOTYPES. A MULTITUDE OF DATA DEMONSTRATE THAT INDIVIDUALS WITH DIFFERENT APOE GENOTYPES VARY IN THEIR RESPONSES TO INFLAMMATORY STIMULI, AND APOE- MODULATED NEUROINFLAMMATION IS EMERGING AS A POTENTIAL NEW MEDIATOR OF APOE GENOTYPE-SPECIFIC COGNITIVE DECLINE. WE PROPOSE THAT THE GASTROINTESTINAL (GI) AND PERIPHERAL IMMUNE SYSTEMS REPRESENT A LIKELY BRIDGE BETWEEN INFECTION OR MICROBIAL DYSBIOSIS AND NEUROINFLAMMATION, AND THAT NEUTROPHILS, AS THE MOST ABUNDANT LEUKOCYTE WITH GREAT POTENTIAL FOR INFLAMMATORY DAMAGE, MEDIATE ALTERED RESPONSES IN INDIVIDUALS WITH DIFFERENT APOE ALLELES TO DRIVE NEUROINFLAMMATION AND COGNITIVE DECLINE. OUR HYPOTHESIS IS THAT APOE4 INCREASES NEUTROPHIL ACTIVATION AND LIFESPAN IN THE GI, PERIPHERY, AND BRAIN, THUS CONTRIBUTING TO NEUROINFLAMMATION AND COGNITIVE DECLINE. THIS HYPOTHESIS IS BASED ON COMPELLING EVIDENCE FROM PUBLISHED WORK AND OUR PRELIMINARY DATA. STUDIES HAVE DEMONSTRATED THAT NEUTROPHILS INFILTRATE THE BRAIN VASCULATURE AND PARENCHYMA DURING AD AND NEUTROPHIL ACTIVATION IN THE PERIPHERY CORRESPONDS WITH DISEASE PROGRESSION IN AD. OUR PRELIMINARY DATA SUGGESTS THAT APOE ALTERS NEUTROPHIL ACTIVATION IN A GENOTYPE- SPECIFIC MANNER, AS HAS BEEN OBSERVED PREVIOUSLY IN GLIAL CELLS. WE WILL ADDRESS OUR HYPOTHESIS AND ACHIEVE OUR STUDY GOALS BY PURSUING THE FOLLOWING THREE AIMS: 1) INVESTIGATE NEUTROPHIL LIFESPAN, ACTIVATION, AND FUNCTIONALITY IN THE GI TRACT, PERIPHERY, AND BRAIN BASED ON APOE GENOTYPE AND AGE IN MICE EXPRESSING HUMAN APOE2, APOE3, AND APOE4 UNDER THE ENDOGENOUS PROMOTOR (APOE-TR); 2) INVESTIGATE MICROBIOME CHANGES LONGITUDINALLY IN APOE-TR MICE AND APOE MODULATION OF NEUTROPHIL RESPONSES TO APOE GENOTYPE-SPECIFIC COMMENSAL BACTERIA AND A; AND 3) INVESTIGATE NEUTROPHILS AS MECHANISTIC DRIVERS OF NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT IN RESPONSE TO INFLAMMATORY STIMULI IN THE CONTEXT OF DIFFERENT APOE GENOTYPES. THIS PROJECT IS SIGNIFICANT BECAUSE NO STUDIES HAVE INVESTIGATED APOE-SPECIFIC NEUTROPHIL RESPONSES DESPITE A PROPOSED ROLE FOR NEUTROPHILS IN AD. THIS PROJECT IS TRANSLATIONALLY INNOVATIVE AND ACTIONABLE BECAUSE THE INFORMATION GAINED WILL INFORM THE TESTING OF NEUTROPHIL-TARGETED OR MICROBIAL-TARGETED THERAPEUTIC APPROACHES IN AD MOUSE MODELS AND HUMANS AND DETERMINE IF THEY SHOULD BE TAILORED BASED ON APOE GENOTYPE.